

Supplementary file

Supplementary Table S1. Clinical characteristics of RA patients included in this study.

RA Patient Code	RF	ACPA	Treatment	Disease duration (years)
35	high	high	mtx 7.5/week, prednisone or equivalent <5 mg/day	3
77	high	high	none	<1
97	high	low	none	<1
102	high	high	methotrexate 7.5 mg/w, prednisone or equivalent <10 mg/d	<1
116	high	high	prednisone or equivalent <5 mg/day	<1
170	high	low	none	<1
BP124	high	high	prednisone or equivalent <5 mg/day	<1
LB11	high	neg	adalimumab 40 mg/2w, leflunomide 20 mg/d, prednisone or equivalent <5 mg/d	4
LB12	high	high	methotrexate 15 mg/w, prednisone or equivalent <5 mg/d	
LB13	low	low	none	<1
LB15	neg	neg	adalimumab 40 mg/2w, nsaid	3
LB19	neg	neg	none	1
LB20	high	low	prednisone or equivalent <5 mg/day	<1
LB23	neg	neg	methotrexate 17.5/week, prednisone or equivalent <5 mg/day	
LB26	low	low	none	<1
LB29	neg	neg	hydroxychloroquine	2
LB30	high	high	hydroxychloroquine, prednisone or equivalent <5 mg/day	2
LB4	low	low	none	<1
LB5	high	low	none	<1
LB6	high	high	sulfasalazine, prednisone or equivalent <5 mg/day	20
LB9	neg	neg	methotrexate 7.5 mg/w,	3

Supplementary Table S2. Primers used in RT-qPCR experiments.

Genes	Forward	Reverse	Product length (bp)
<i>H60a</i>	CCAGTATGGTCCCAGATAGC	GAGCCACCAGCAAGAGCAA	75
<i>H60b</i>	AGCCTTTTGGTCCTGCTGAAT	ATGTTTTTATCACCAAAATCAAGGAGT	150
<i>H60c</i>	AAATGCCAACCTTGCCAACC	CCATCAAAGGGGCTGGACTT	79
<i>Rae1 δ Rae 1 ε</i>	CAGCTGTTGCCACAGTCAC	CGTTGGTGTATCCATAGCTCA	118
<i>Mult1</i>	GTCACCTGTGTTTATGCAGATTG	TCGTCTGAAGTCAACAGCAC	147
<i>Klrk1</i>	GCCAGCAAAGTGGGATACTTCTCAA	CAAGGACTCGAACAACGAACATTGG	146
<i>Gapdh</i>	CCCTTAAGAGGGATGCTGGG	TACGGCCAAATCCGTTTACA	124
<i>Hprt</i>	AGTCCCAGCGTCGTGATTAG	TGATGGCCTCCCATCTCCTT	170
<i>Actin</i>	CACTGTCGAGTCGCGTCCA	CATCCATGGCGAACTGGTGG	88